Enter Note Done
Go to previous page in this tab
Event
  • Scientific Session
  • Bookmark Icon
  • Comparative Approaches to Safety Evaluation of Cosmetics: Toxicological Paradigms, Risk Assessment Frameworks, and Regulatory Decision-Making
  • Schedule
    Notes
  • Stars at Night Ballroom B2‚ Convention Center
    Set Timezone


Chair: Abdel-Razak Kadry, University of Maryland School of Public Health
Co-Chair: Bob Sonawane, International Risk & Toxicology Institute LLC

Primary Endorser: Arab Toxicologists Association Special Interest Group


Endorser(s): Toxicologists of African Origin Special Interest Group


Endorser(s): Association of Scientists of Indian Origin Special Interest Group


Cosmetic safety regulation remains one of the most fragmented areas in applied toxicology, shaped by differing scientific paradigms, legal frameworks, and approaches to managing uncertainty. This session will examine how regulatory authorities in the European Union, United States and other developing countries interpret toxicological data to inform safety decisions, with implications for innovation, and global trade.

The European Union’s precautionary, hazard-based framework stands in contrast to the United States’ exposure-driven, post-market approach, recently updated through the Modernization of Cosmetics Regulation Act (MoCRA, 2022). Other developing countries operate within hybrid models, adding further complexity to the global landscape. At the same time, international initiatives such as the International Cooperation on Cosmetics Regulation (ICCR) and its Integrated Strategies for Safety Assessment (ISSA) Joint Working Group (JWG) are advancing next-generation risk assessment (NGRA) approaches and promoting alternatives to animal testing.

The session will explore key areas where these approaches diverge, including hazard versus risk-based decision-making, endocrine disruption, quantitative risk assessment for sensitization, margin of safety interpretation, and the evaluation of impurities and degradation products. For example, the U.S. FDA restricts only a small number of cosmetic ingredients, not because others are confirmed safe, and regulation is largely post-market. In contrast, the EU applies a more precautionary approach, prohibiting over 1,000 substances and requiring premarket evaluation review.

Session and Activity Type
Presentations